Q-omics provides the consensus-scored ADGRL1 profile across patient tissues and cancer cell-line models. ADGRL1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ADGRL1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ADGRL1 protein abundance shows 30,052 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where ADGRL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADGRL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADGRL1 survival associations across molecular data types. ADGRL1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADGRL1 RNA expression–survival associations across cancer types. High ADGRL1 expression shows unfavorable associations in UVM and ACC, but favorable associations in LGG, SCLC, HNSC and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ADGRL1 RNA expression.
This table summarizes ADGRL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ADGRL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADGRL1 shows lower tumor expression in KIRC and LUAD and higher tumor expression in COAD, LIHC, HNSC and LUSC. The KIRC box plot shows higher ADGRL1 RNA expression in normal versus tumor tissue (log2 FC = −1.631, t-test p < 0.001).
This table shows molecular features associated with ADGRL1 in patient tissues and cancer cell lines. In patient samples, ADGRL1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADGRL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
